drugset / Trial / NCT03303911
A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of this study are: * To evaluate the pharmacokinetic (PK) parameters during repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule. * To evaluate the pharmacodynamic (PD) effects (e.g., reduction in smoking) with repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule.
Timeline
- Start
- 2017-10-06
- Primary completion
- 2018-10-05
- Completion
- 2018-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytisinicline | Small molecule | 1.5 mg | — |
| Subject | Cytisinicline | Small molecule | 3 mg | — |
Indications
No indication recorded.